by Gina Shaw
ViiV Healthcare, a global HIV company with GlaxoSmithKline, Pfizer Inc. and Shionogi Limited as shareholders, with Janssen Sciences Ireland announced on Jan. 7 that they had formalized an agreement for the Phase III investigation and commercialization of the two-drug combination of long-acting, injectable formulations of ViiV’s investigational cabotegravir and Janssen’s rilpivirine (Edurant) for the treatment of HIV. The combination is being investigated as an